Trial of Decitabine in Patients With Acute Myeloid Leukemia
Acute Myeloid Leukemia
About this trial
This is an interventional treatment trial for Acute Myeloid Leukemia focused on measuring Acute Myeloid Leukemia, Dacogen, Decitabine, Poor or intermediate-risk cytogenetics
Eligibility Criteria
Inclusion Criteria: Must have diagnosed acute myeloid leukemia. Must have a life expectancy of at least 12 weeks. Must sign informed consent. Exclusion Criteria: Must not have acute promyelocytic leukemia (M3 classification) Must not have any other active systemic malignancies. Must not have inaspirable bone marrow. Must not have received previous chemotherapy (except hydroxyurea) for any myeloid disorder. Must not have chronic respiratory disease that requires continuous oxygen use. Must not have received any experimental drug within 4 weeks before randomization. Must not be a candidate for a bone marrow or stem cell transplant within 12 weeks after randomization. Must not have known HIV.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
A
B
Subject's choice of treatment with physician's advice. Subjects preselected their preference of supportive care (including IV fluids, nutrition, and antibiotics) or cytarabine. (These represent one intervention.)